Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/10065
Title: MDX-060. Medarex.
Austin Authors: Hu, Xiu Feng;Xing, Pei Xiang
Affiliation: The Austin Research Institute, Austin Health, Heidelberg 3084, Victoria, Australia
Issue Date: 1-Dec-2005
Publication information: Current Opinion in Investigational Drugs (london, England : 2000); 6(12): 1266-71
Abstract: Medarex is developing the antibody MDX-060 for the potential treatment of CD30+ lymphomas, such as Hodgkin's disease and anaplastic large cell lymphomas. Phase I/II clinical trials were underway by December 2002.
Gov't Doc #: 16370393
URI: http://ahro.austin.org.au/austinjspui/handle/1/10065
URL: https://pubmed.ncbi.nlm.nih.gov/16370393
Type: Journal Article
Subjects: Animals
Antibodies, Monoclonal
Antigens, CD30.immunology
Antineoplastic Agents.pharmacology.therapeutic use
Clinical Trials as Topic
Drug Screening Assays, Antitumor
Hodgkin Disease.drug therapy.immunology
Humans
Lymphoma, Large B-Cell, Diffuse.drug therapy.immunology
Appears in Collections:Journal articles

Show full item record

Page view(s)

6
checked on Dec 7, 2022

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.